Rana Zabad, MD, FAAN

Rana Zabad, MDProfessor - Department of Neurological Sciences
Chief - Multiple Sclerosis/Neuroimmunology Section
Program Director - Multiple Sclerosis Fellowship

Clinical Practice:
Academic Office:
4242 Farnam Street, Suite 650
North Doctor's Tower
Omaha, NE 68131
Phone: 402-559-8600
Fax: 402-559-3545

988440 Nebraska Medical Center
Omaha, NE 68198-8440
Fax: 402-559-3341

Education: 

Hospital Appointments:
University of Nebraska Medical Center
VA Nebraska-Western Iowa Health Care System

Interests:
Multiple Sclerosis/Neuroimmunology, neurosarcoidosis, CNS vasculitis, autoimmune diseases affecting the brain.

Biographical Sketch:
Dr. Rana K. Zabad is a Professor and Director of the Multiple Sclerosis Program at the University of Nebraska Medical Center since October 2008. Dr. Zabad received her medical degree from St. Joseph University in Beirut, Lebanon, completed her internship and neurology residency at the Detroit Medical Center, Wayne State University School of Medicine in Detroit, Michigan. She further went for a fellowship in MS Neuroimmunology for 3 years at the University of Calgary in Calgary, Alberta, Canada under the mentorship of Drs. Luanne Metz and Wee Yong. Dr. Zabad is board certified by the American Board of Psychiatry and Neurology and a member of the American Academy of Neurology, the American Medical Association, National MS Society, Nebraska Chapter, the Consortium of MS centers, the United Leukodystrophy Foundation and the International Association of Health Care professionals. Dr. Zabad is a receiver of the Who’s Who award in Medicine in 2002.

Dr. Zabad presents at 2019 Multiple Sclerosis Symposium

Dr. Zabad's Active Clinical Research:
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis (“OPERA” Study Program)